Insider Purchases: Inside the Buy
Tag: InsiderBuys
CEO Had Bought Lots of Shares and Petco (WOOF) Finally Turns a Profit?
Petco (WOOF) shocked Wall Street with a surprise profit and a 23.5% stock jump. Insiders—including the CEO—have been buying millions of shares, while institutions hold more than 120% of the float. Can Petco’s bark finally match its bite?
Insiders Are Buying ConocoPhillips. Should You?
Insiders are drilling into COP shares—and they're not alone. With a $10B return plan, strong reserves, and a smart buyout of Marathon Oil, ConocoPhillips might just be the contrarian pick of the year. Here's the fun, smart breakdown.
Oxford Industries’s Tommy Bahama and Lilly Pulitzer Rock: Should You Emulate Insiders and Buy More Than the Brands?
Oxford Industries owns some of the most recognizable lifestyle brands—Tommy Bahama, Lilly Pulitzer, and Johnny Was. Sales are soft, but margins hold, insiders are buying, and the dividend is sweet. Time to sip a piña colada—and check the stock price?
Oscar Health: Its Own Is Shining and Insiders Knew!
Co-founder Joshua Kushner and Thrive Partners bought over $23 million of Oscar Health stock in late 2024. Since then? Record earnings, soaring revenue, and a stock still (surprisingly) within range. A healthy bet — or just a well-insured hunch?
Vera Bradley: The Bags Are Pretty; the Financials? Not So Much
The bags? Still adorable. The stock? Still near record lows. With insiders finally buying and a CEO exit underway, is Vera Bradley set for a stylish rebound — or is it still stuck in the clearance bin?
Magnera: Insiders Keep Buying… Should You?
Magnera’s boardroom is buying diapers—literally. With insiders piling in and free cash flow returning, this specialty materials firm might be worth more than just its wipes. But don’t forget the debt and diaper jokes.
Can Lyft Ever Lift Off or Will It Forever Uber-Underwhelm?
CEO David Risher has been scooping up Lyft shares like surge-priced burritos—and with record rides, rising cash flow, and a $750M buyback plan, the bullish case is stronger than ever. But can LYFT finally fly—or is Uber still driving the narrative?
Ligand Pharmaceuticals (LGND): In a League of Its Own? Insiders Think So!
Ligand Pharma (LGND) isn’t chasing moonshots—it’s collecting royalties across a sprawling biotech empire. With both the CEO and CFO buying in, and a royalty engine showing 46% revenue growth, insiders may know something. Is this the most compelling quiet biotech turnaround on the Nasdaq?
🥞 Pra Group: No Fun to Get Their Call But Fun to Call Their Stock!
They buy bad debt for pennies, chase it like bounty hunters, and sometimes spin a tidy profit from society’s financial skeletons. But is PRA Group (PRAA) a hidden gem—or a value trap in disguise? We dig deep into this curious case.